Adegramotide/nelatimotide

Drug Profile

Adegramotide/nelatimotide

Alternative Names: Adegramotide and nelatimotide; DSP-7888

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Developer Boston Biomedical; Kyoto Prefectural University of Medicine; Sumitomo Dainippon Pharma; Wakayama Medical University
  • Class Antineoplastics; Peptide vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Brain cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Glioma; Myelodysplastic syndromes; Soft tissue sarcoma
  • Phase I Haematological malignancies; Pancreatic cancer; Solid tumours

Most Recent Events

  • 30 Oct 2017 Phase-II clinical trials in Glioblastoma (Combination therapy, Recurrent) in Canada (Intradermal), Japan (Intradermal) (Sumitomo Dainippon Pharma pipeline, November 2017)
  • 23 Oct 2017 Boston Biomedical plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in November 2017 (NCT03311334)
  • 12 Oct 2017 Phase I development for Solid tumours and Haematological malignancies (Late-stage disease) is ongoing in USA (NCT02498665)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top